Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.

@article{Bambury2016NovelAN,
  title={Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.},
  author={Richard Martin Bambury and Dana E. Rathkopf},
  journal={Urologic oncology},
  year={2016},
  volume={34 8},
  pages={348-55}
}
The approval of abiraterone and enzalutamide for the treatment of advanced castration-resistant prostate cancer heralded a paradigm shift in the management of this disease. Nevertheless, new and improved treatments are needed since the disease remains incurable for the majority of these patients. In this article, we review the biology of castration-resistant disease as well as emerging therapeutic compounds directed at the androgen receptor, including galeterone, VT-464, ARN-509, and ODM-201… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS

References

Publications referenced by this paper.
Showing 1-10 of 78 references

Galeterone in four castrate resistant prostate cancer populations: results from ARMOR2

  • ME Taplin, KN Chi, F Chu, J Cochran, WJ Edenfield, M Eisenberger
  • ESMO Congress;
  • 2014
Highly Influential
4 Excerpts

Enzalutamide in patients with high-risk prostate cancer

  • J. Garcia
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…